Loading organizations...
Loading organizations...
Sequenta is a technology company.
Sequenta develops clinical diagnostics through a proprietary platform designed to analyze the immune system. Their core product, ClonoSEQ, is a minimal residual disease assay utilized for the precise detection and monitoring of various lymphoid cancers, including leukemia and lymphoma. This advanced methodology offers clinicians a highly sensitive tool for tracking disease burden and assessing treatment efficacy.
Tom Willis and Malek Faham co-founded Sequenta in 2008, building upon their previous success as co-founders of ParAllele BioScience. Their foundational insight centered on harnessing high-throughput sequencing to deeply characterize the immune repertoire, recognizing its untapped potential for creating exceptionally sensitive and specific diagnostic solutions in oncology.
The company primarily serves oncologists and hematologists who treat patients with lymphoid malignancies. Sequenta's long-term vision is to profoundly improve patient care by providing innovative diagnostic insights derived from immune system analysis, thereby enabling more informed clinical decisions and advancing personalized medicine in immune-mediated diseases.
Sequenta has raised $41.0M across 3 funding rounds.
Sequenta has raised $41.0M in total across 3 funding rounds.
# Sequenta: A Technology Company Overview
The search results reveal multiple companies with similar names, making it essential to clarify which Sequenta you're asking about. The most prominent results show three distinct entities:
1. Sequentia Technologies (Bangalore, India) – a fabless semiconductor company specializing in FPGA/verification solutions
2. Sequenta (biotechnology) – a clinical diagnostics company focused on immune cell diseases
3. Sequentia (India) – an outsourced product development firm offering AI, ML, and data science services
Given your framing as "a technology company," I'll address the most likely candidate based on available information.
Sequentia (the India-based technology services firm) operates as an outsourced product development provider specializing in data science, artificial intelligence, and machine learning technologies.[3] The company serves enterprises seeking to modernize their operations through digital transformation, offering services across product engineering, digital experience design, and enterprise solutions.
The company positions itself as a "new-age provider" addressing the growing demand for specialized technical expertise in emerging technologies. Its service portfolio spans multiple domains including mobile app development, enterprise content management, and agile enterprise transformation—indicating a broad approach to helping organizations navigate digital modernization.
Sequentia operates within the outsourced product development and digital transformation sector, which has grown substantially as enterprises increasingly rely on specialized vendors for AI/ML implementation and modernization. The company's positioning reflects broader market trends: organizations recognizing that building in-house expertise for emerging technologies is costly, and outsourced development partnerships offer faster time-to-market and access to specialized talent pools.
As an established outsourced development firm, Sequentia's trajectory depends on sustained enterprise demand for AI/ML services and digital transformation consulting. The company's success will likely hinge on its ability to differentiate in an increasingly crowded market of development service providers and maintain technical excellence as AI capabilities become more commoditized.
Note: If you intended to inquire about Sequentia Technologies (the semiconductor company) or Sequenta (the biotech diagnostics firm), please clarify, and I can provide a more targeted analysis of that specific organization.
Sequenta has raised $41.0M in total across 3 funding rounds.
Sequenta's investors include Foresite Capital, Nokia Growth Partners, Wildcat Ventures.
Sequenta has raised $41.0M across 3 funding rounds. Most recently, it raised $20.0M Series C in July 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2013 | $20.0M Series C | Foresite Capital, Nokia Growth Partners, Wildcat Ventures | |
| Dec 1, 2011 | $8.0M Venture Round | Nokia Growth Partners, Wildcat Ventures | |
| Dec 1, 2010 | $13.0M Series B | Nokia Growth Partners, Wildcat Ventures |